Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded by Leerink Partnrs to Strong-Buy Rating

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating in a note issued to investors on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for Rhythm Pharmaceuticals' Q2 2025 earnings at ($0.87) EPS, Q3 2025 earnings at ($0.90) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.49) EPS, FY2026 earnings at ($2.86) EPS, FY2027 earnings at ($2.07) EPS, FY2028 earnings at ($0.42) EPS and FY2029 earnings at $1.28 EPS.

RYTM has been the topic of several other reports. Wells Fargo & Company increased their target price on Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the stock an "overweight" rating in a research report on Monday, April 7th. Bank of America upgraded Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $63.00 target price on the stock in a research report on Monday, April 7th. Canaccord Genuity Group raised their price objective on Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the stock a "buy" rating in a report on Tuesday, April 8th. Leerink Partners assumed coverage on Rhythm Pharmaceuticals in a report on Monday, July 7th. They issued an "outperform" rating and a $88.00 price objective on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $80.00 price objective (up from $70.00) on shares of Rhythm Pharmaceuticals in a report on Tuesday, April 8th. Fourteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $91.00.

Rhythm Pharmaceuticals Stock Down 2.6%

Shares of RYTM traded down $2.34 during trading hours on Monday, reaching $86.70. 1,105,173 shares of the company traded hands, compared to its average volume of 588,517. The stock has a market capitalization of $5.52 billion, a PE ratio of -30.85 and a beta of 2.26. Rhythm Pharmaceuticals has a fifty-two week low of $40.61 and a fifty-two week high of $94.80. The stock has a fifty day simple moving average of $64.34 and a 200 day simple moving average of $59.29.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.12). The company had revenue of $37.72 million for the quarter, compared to analyst estimates of $40.43 million. Rhythm Pharmaceuticals had a negative net margin of 123.26% and a negative return on equity of 739.62%. The firm's revenue was up 25.9% on a year-over-year basis. During the same period in the previous year, the business earned ($2.35) EPS. Research analysts predict that Rhythm Pharmaceuticals will post -4.32 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Christopher Paul German sold 3,817 shares of the stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $80.75, for a total value of $308,222.75. Following the completion of the sale, the chief accounting officer owned 922 shares in the company, valued at approximately $74,451.50. This trade represents a 80.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Pamela J. Cramer sold 15,572 shares of the stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $77.13, for a total value of $1,201,068.36. Following the completion of the sale, the insider owned 19,209 shares of the company's stock, valued at approximately $1,481,590.17. This trade represents a 44.77% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 93,673 shares of company stock valued at $7,118,510. Company insiders own 6.10% of the company's stock.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Rhythm Pharmaceuticals during the 1st quarter valued at approximately $34,000. SBI Securities Co. Ltd. acquired a new stake in Rhythm Pharmaceuticals during the 4th quarter valued at approximately $37,000. State of Wyoming acquired a new stake in Rhythm Pharmaceuticals during the 4th quarter valued at approximately $61,000. GF Fund Management CO. LTD. acquired a new stake in Rhythm Pharmaceuticals during the 4th quarter valued at approximately $72,000. Finally, CWM LLC grew its stake in Rhythm Pharmaceuticals by 92.3% during the 1st quarter. CWM LLC now owns 2,584 shares of the company's stock valued at $137,000 after purchasing an additional 1,240 shares in the last quarter.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.